ong-term study of M606102 in the treatment of axillary hyperhidrosis

The once-daily application of M606102 was effective for the patients with primary axillary hyperhidrosis. The incidences of drug-related adverse event and other significant adverse event were high in the 3.75% M606102 group compared to the 2.5% M606102 group; most of the adverse events were mild in the severity and the outcomes were "recovered" or "recovering". Therefore, the long-term application was considered tolerated in both treatment groups.